The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > ORGANIZATION
ORGANIZATION
- Gap between Poll Results and Drug Availability “Inevitable,” FPMAJ Says after JMA’s Criticism
November 22, 2023
- New Group Led by MRI to Issue Clinical Trial Policy Proposals by September 2024
November 22, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
- PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
- Diabetes Groups Urge Govt to Build Stable Supply System for GLP-1s, Other Meds
November 8, 2023
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- GHIT Fund, MPP to Bolster Ties to Enhance Drug Access
October 31, 2023
- 70% of Younger Wholesaler Staffers Ponder Quitting Jobs amid Supply Crunch: Poll
October 30, 2023
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
- JMA to Seek Wage Hike of “at Least 3%” in 2024 Revision: President
October 27, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Off-Label Use of GLP-1 Goes against Medical Ethics: JMA Executive
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Neurology Society, SMA Group Urge Nationwide Newborn Test at Public Expense
October 20, 2023
- No Info Received from Member Firms on Impact of Middle East Crisis: JPMA
October 20, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…